EP3 Stock Overview Provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
OraSure Technologies, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for OraSure Technologies Historical stock prices Current Share Price US$3.80 52 Week High US$7.05 52 Week Low US$3.42 Beta 0.048 1 Month Change 11.11% 3 Month Change 2.70% 1 Year Change -44.53% 3 Year Change -51.44% 5 Year Change -38.71% Change since IPO -31.53%
Recent News & Updates
Nowdiagnostics, Inc. Files Countersuit Against Frivolous Orasure Claims Jan 15
Nowdiagnostics, Inc. Files Countersuit Against Frivolous Orasure Claims Jan 14
OraSure Technologies, Inc.'s OraQuick HIV Self-Test Receives Approval for Use in Adolescents Jan 08 OraSure Technologies, Inc. (NasdaqGS:OSUR) acquired Sherlock Biosciences, Inc. from a group of shareholders. Dec 20
OraSure Technologies, Inc. Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test from Biomedical Advanced Research and Development Authority Dec 03
OraSure Technologies, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024 Nov 08 See more updates
Nowdiagnostics, Inc. Files Countersuit Against Frivolous Orasure Claims Jan 15
Nowdiagnostics, Inc. Files Countersuit Against Frivolous Orasure Claims Jan 14
OraSure Technologies, Inc.'s OraQuick HIV Self-Test Receives Approval for Use in Adolescents Jan 08 OraSure Technologies, Inc. (NasdaqGS:OSUR) acquired Sherlock Biosciences, Inc. from a group of shareholders. Dec 20
OraSure Technologies, Inc. Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test from Biomedical Advanced Research and Development Authority Dec 03
OraSure Technologies, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024 Nov 08
Third quarter 2024 earnings released: US$0.06 loss per share (vs US$0.15 profit in 3Q 2023) Nov 08
OraSure Technologies, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
OraSure Technologies, Inc. Appoints John P. Kenny as New Member of the Board, Member of the Nominating and Corporate Governance Committee Sep 11
New minor risk - Share price stability Aug 08
Second quarter 2024 earnings released: US$0.008 loss per share (vs US$0.065 loss in 2Q 2023) Aug 07 OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2024
OraSure Technologies, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 23
New minor risk - Shareholder dilution May 10
OraSure Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2024 May 10
First quarter 2024 earnings released: US$0.048 loss per share (vs US$0.37 profit in 1Q 2023) May 09
New minor risk - Shareholder dilution Apr 05
OraSure Technologies, Inc., Annual General Meeting, May 14, 2024 Apr 04 OraSure Technologies, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023
New minor risk - Earnings quality Feb 29
Full year 2023 earnings released: EPS: US$0.73 (vs US$0.25 loss in FY 2022) Feb 28
OraSure Technologies, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024 Feb 14
Investor sentiment improves as stock rises 22% Nov 15
OraSure Technologies, Inc. Provides Financial Guidance for the Fourth Quarter 2023 Nov 08
Third quarter 2023 earnings released: EPS: US$0.15 (vs US$0.073 in 3Q 2022) Nov 08
OraSure Technologies, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 24
New major risk - Share price stability Oct 13
Investor sentiment improves as stock rises 27% Aug 11
New major risk - Share price stability Aug 08
OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2023 Aug 04
Second quarter 2023 earnings released: US$0.065 loss per share (vs US$0.26 loss in 2Q 2022) Aug 04
OraSure Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
OraSure Technologies, Inc. Announces Election of Robert W. McMahon to its Board of Directors, Effective July 31, 2023 Jul 22
OraSure Technologies, Inc. Announces Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access Jun 14
Investor sentiment improves as stock rises 18% Jun 05
Chief Financial Officer recently bought €460k worth of stock Jun 02
Investor sentiment deteriorates as stock falls 20% May 17
Orasure Technologies, Inc. Provides Earnings Guidance for the Second Quarter 2023 May 12
First quarter 2023 earnings released: EPS: US$0.37 (vs US$0.28 loss in 1Q 2022) May 11
OraSure Technologies, Inc. to Report Q1, 2023 Results on May 10, 2023 May 04
Full year 2022 earnings released: US$0.25 loss per share (vs US$0.32 loss in FY 2021) Feb 16
OraSure Technologies, Inc. Provides Revenue Guidance for the First Quarter of 2023 Feb 15
OraSure Technologies, Inc. to Report Q4, 2022 Results on Feb 14, 2023 Feb 08
High number of new directors Nov 16
OraSure Technologies, Inc. Announces Executive Changes Nov 16
Third quarter 2022 earnings released: EPS: US$0.073 (vs US$0.21 loss in 3Q 2021) Nov 10 OraSure Technologies, Inc. Reports Goodwill and Long-Lived Assets Impairment Charges for the Third Quarter Ended September 30, 2022
Orasure Technologies Receives General Clearance for Its ORAcollect--Dx Device for over the Counter Use from the U.S. Food and Drug Administration Nov 04
OraSure Technologies, Inc. Announces InteliSwab Covid-19 Rapid Test Now Available in Amazon’s Online Store Nov 03
OraSure Technologies, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Independent Director recently bought €200k worth of stock Aug 30
Independent Chairman of the Board recently bought €53k worth of stock Aug 17
Second quarter 2022 earnings released: US$0.26 loss per share (vs US$0.019 loss in 2Q 2021) Aug 11 OraSure Technologies, Inc. Announces CFO Changes OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2022
OraSure Technologies, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Aug 03
OraSure Technologies, Inc. Announces Executive Changes Jul 16
OraSure Technologies LaunchesNewProduct for Microbiome Researchers to Study DNA and RNA Jul 15 OraSure Technologies, Inc.(NasdaqGS:OSUR) dropped from Russell 2000 Value-Defensive Index
OraSure Technologies, Inc. Announces Resignation of Agnieszka M. Gallagher as Executive Vice President, General Counsel and Chief Compliance Officer, Effective June 25, 2022 Jun 11 OraSure Technologies, Inc. Appoints Carrie Eglinton Manner as President, Effective June 4, 2022
OraSure Technologies, Inc. Announces That Its InteliSwab® Covid-19 Rapid Tests Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants May 18
First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.053 profit in 1Q 2021) May 11
High number of new directors Apr 27
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
OraSure Technologies, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 17
Orasure Technologies, Inc. Announces Inteliswab® Covid-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New Inteliswab® Connect Reporting App Feb 01
OraSure Technologies, Inc. Updates Revenue Guidance for the Fourth Quarter of 2021 Jan 06
High number of new directors Jan 01
High number of new directors Dec 02
Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.015 profit in 3Q 2020) Nov 05
OraSure Technologies, Inc. to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver Sep 24
CFO & Principal Accounting Officer Roberto Cuca has left the company Sep 23
Orasure Technologies, Inc. Provides Revenue Guidance for the Third Quarter and Fiscal Year 2021 Aug 05
Second quarter 2021 earnings released: US$18.95 loss per share (vs US$0.16 loss in 2Q 2020) Aug 04
Director Mara Aspinall has joined 5th company board Aug 04
Director Mara Aspinall has joined 5th company board Aug 04
Director Mara Aspinall has joined 5th company board Aug 04
Director Mara Aspinall has joined 5th company board Aug 04
Director Mara Aspinall has joined 5th company board Aug 04
Director Mara Aspinall has joined 5th company board Aug 04
Director Mara Aspinall has joined 5th company board Aug 04 OraSure Technologies, Inc.(NasdaqGS:OSUR) dropped from Russell Small Cap Comp Growth Index
OraSure Technologies Receives Three Emergency Use Authorizations for its COVID-19 Rapid Antigen Tests for Non-Prescription, Professional and Prescription Use Jun 08
OraSure Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2021 May 07
First quarter 2021 earnings released: EPS US$0.053 (vs US$0.12 loss in 1Q 2020) May 06
Full year 2020 earnings released: US$0.22 loss per share (vs US$0.27 profit in FY 2019) Mar 02
Revenue beats expectations Mar 02
New 90-day low: €8.40 Feb 25 Shareholder Returns EP3 DE Medical Equipment DE Market 7D 1.1% 2.9% 1.9% 1Y -44.5% -1.0% 15.1%
See full shareholder returns
Return vs Market: EP3 underperformed the German Market which returned 15.2% over the past year.
Price Volatility Is EP3's price volatile compared to industry and market? EP3 volatility EP3 Average Weekly Movement 5.5% Medical Equipment Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: EP3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: EP3's weekly volatility (6%) has been stable over the past year.
About the Company OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services.
Show more OraSure Technologies, Inc. Fundamentals Summary How do OraSure Technologies's earnings and revenue compare to its market cap? EP3 fundamental statistics Market cap €287.12m Earnings (TTM ) €10.97m Revenue (TTM ) €216.35m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EP3 income statement (TTM ) Revenue US$224.26m Cost of Revenue US$114.79m Gross Profit US$109.47m Other Expenses US$98.10m Earnings US$11.37m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/31 05:11 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources OraSure Technologies, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Charley Jones Barrington Research Associates, Inc. Karen Koski BTIG Mark Massaro Canaccord Genuity
Show 14 more analysts 
